Starpharma Holdings Limited (ASX:SPL)

Market Cap	196.69M +42.5%
Revenue (ttm)	12.67M +116.5%
Net Income	-7.47M
EPS	-0.02
Shares Out	479.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	990,328
Open	0.4500
Previous Close	0.4500
Day's Range	0.4050 - 0.4500
52-Week Range	0.3200 - 0.8750
Beta	0.85
Analysts	n/a
Price Target	1.22 (+197.56%)
Est. Earnings	Nov 16, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 50
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SPL

Financial Performance

In fiscal year 2026, Starpharma Holdings's revenue was 12.67 million, an increase of 116.55% compared to the previous year's 5.85 million. Losses were -7.47 million, -25.28% less than in 2025.

Analyst Summary

The average 12-month stock price target for SPL is $1.22, which is an increase of 197.56% from the latest price.

Price Target

$1.22

(197.56% upside)

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error